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ABOUT HEPP
HEPP News, a forum for 
correctional problem solving, 
targets correctional administrators
and HIV/AIDS care providers including
physicians, nurses, outreach workers,
and case managers. Published monthly
and distributed by fax, HEPP News 
provides up-to-the-moment informa-
tion on HIV treatment, efficient
approaches to administering HIV treat-
ment in the correctional environment,
national and international news related
to HIV in prisons and jails, and changes
in correctional care that impact 
HIV treatment.  Continuing Medical
Education credits are provided by the
Brown University Office of Continuing
Medical Education to physicians who
accurately respond to the questions on
the last page of the newsletter.  
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at the end of articles. All of the individual
medications discussed in this newsletter
are approved for treatment of HIV unless
otherwise indicated. For the treatment of
HIV infection, many physicians opt to use
combination antiretroviral therapy which
is not addressed by the FDA.
HEPP News is grateful for the primary 
support of Agouron Pharmaceuticals and 
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HIV in correctional settings is beginning to infil-
trate our nation’s political theater.  In response
to this new development, the National
Commission on Correctional Health chose
prominent political leader Reverend Jesse
Jackson Sr. to open this year’s National
Conference on Correctional Healthcare
(NCCHC), held September 9-13 in St Louis,
Missouri. 
NCCHC is the largest nationwide educational
gathering of physicians, nurses, dentists, psy-
chiatrists, psychologists, other health care pro-
fessionals, administrators, attorneys, and oth-
ers working in prisons, jails, juvenile confine-
ment, and detention facilities.  Participants had
an opportunity to meet and network with experts
as they discussed current correctional health
issues. Recent developments in the manage-
ment and treatment of HIV were featured in a
special track of programs throughout the con-
ference.
Illustrating correctional health care’s most pop-
ular issues, the pre-conference seminars fea-
tured NCCHC’s standards and mental health
care guidelines, an introduction and an
advanced look at quality assessment, practical
preparations for NCCHC accreditation, and
measuring outcomes of HIV interventions.
HEPP Symposium on Outcomes
One way of measuring the potential success, or
outcome, of an intervention is to count the num-
ber of individuals who volunteer to participate.
Based on that measure, the HIV Behind Bars
2000 was a success: attendance at the annual
symposium increased this year to more than
140 individuals, most of whom stayed for the
entire 4 1/2 hour session. 
The focus of the symposium was on "measuring
outcomes." Previous "HIV/AIDS Behind Bars"
sessions have described components of HIV
management (from intake to discharge plan-
ning) and models of care. This year, following
up on a challenge issued by organizer Anne De
Groot at the 4th annual symposium (Ft
Lauderdale, 1999), correctional providers who
had performed an HIV management interven-
tion in a correctional setting and had measured
the impact of that intervention were invited to
present their results.
Outcomes Research Studies
What are outcomes studies? In the HIV/AIDS
arena, outcomes research attempts to measure
the impact of HIV management interventions on
clinical and economic outcomes. Clinical out-
comes are the clinical events and progression
of HIV disease that occur in clinical practice,
and economic outcomes are the economic
events and progression of resource use in HIV
disease that occur in clinical practice.1
Outside corrections, researchers have asked
some hard questions about HIV treatment and
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Figure 1. Cost Effectiveness of 
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Cost effectiveness of HAART, compared to other
medical interventions for other chronic diseases.
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outcomes. For example, given that the life-
time cost of HIV treatment averages
$149,000 (starting at a count of 500 CD4 T
cells2) or from $10,000 to $20,000 per year
of life gained, researchers have compared
this investment to other healthcare invest-
ments. As it turns out, HAART is less
expensive, per year of life gained, than
mammography ($40,0000) and much less
expensive than coronary artery bypass
(see Fig 1.)  In fact, one notable (but less
widely disseminated) outcome of HAART
appears to be that the predicted lifespan of
an individual on HAART with CD4 T cells >
100 is on par with the lifespan of an age-
matched peer who is HIV-seronegative!3
Thus HAART lengthens lifespan more than
most other medical interventions. 
Budgetary Outcomes of 
HIV Care
Other outcomes research has evaluated
the impact of HAART and/or skilled HIV
care on hospitalizations and the incidence
of opportunistic infections, which is more in
line with correctional budgetary concerns.
HAART has clearly been shown in a num-
ber of studies to reduce the development of
opportunistic infections4 and reduce costs
associated with treating these infections.
Therefore, most economic outcomes evalu-
ations of HAART have reported that the
increased cost of treatment was balanced
by a reduction in expenses associated with
hospitalizations and specialty consultations
for opportunistic infections. Furthermore,
care by experienced HIV/AIDS physicians
has been shown to result in two thirds
fewer hospital bed days and fewer special-
ty consultations than care by control (non-
experienced) providers. This is most likely
due to the specialists’ ability to prevent ill-
nesses and toxicities in their patients.
Outcomes studies have also reported on
the cost-effectiveness of interventions for
opportunistic infections in HIV/AIDS
patients. For example, treatment of PPD
positive, HIV-infected individuals is an
extremely cost-effective intervention. By
providing $36 of medication per patient
(INH, 300 mg PO QD for one year) TB
cases can be reduced to neglible propor-
tions (36% reduction).5 
Other researchers have queried whether
HAART prevents other budgetary outlays,
such as hospitalization costs and treatment
of opportunistic infection costs. Indeed,
HAART results in a net savings, especially
in terms of hospitalization costs, in studies
conducted outside corrections.6
Outcomes in Corrections
However, as we’re well aware, studies con-
ducted in community settings are only an
approximation of conditions for HIV-infect-
ed patients behind bars. What information
is available for correctional settings, where
the distribution of costs may be significant-
ly different from the outlay that communities
experience in providing HIV care?
The good news is that outcomes studies
are being funded and performed in correc-
tional settings and there is a new recogni-
tion of the importance of measuring the
impact of an intervention (See Spotlight,
Page 7). The bad news is that few out-
comes studies have been performed and
results are, as yet, unavailable for the
largest of these studies. The HIV Behind
Bars 2000 symposium featured presenta-
tions by a few  "interventionists" who report-
ed their results.
A number of the HIV "stars" of correctional
medicine spoke at the HEPP symposium.
Dr. David Thomas, Medical Director of the
Florida Department of Corrections, Dr. Joe
Bick, Medical Director of the HIV/AIDS
facility at Vacaville, California, Dr. David
Paar of Texas Department of Criminal
Justice, and Dr. Lou Tripoli, Medical
Director for Correctional Medical Services,
all presented information on HIV-related
interventions in their systems. Dr. Joseph
Paris, Medical Director of the Georgia
Department of Corrections moderated the
symposium with characteristic tact and
diplomacy, provided expert audiovisual
support, and reported on outcomes mea-
sures for his state.
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CLINICAL
OUTCOMES
Directly Observed
Therapy (DOT) vs
Self-administered
Therapy (SAT)
% with Viral Loads
below 400
# of patients 
developing 
medication 
side effects
Florida
Directly observed
therapy resulted in
better reductions
(DOT 85% below 5
copies; SAT only
50% below 50
copies)  in viral
loads and fewer toxi-
cities (15% vs 35%).
Fischl, M.,
Rodriguez, A,
Serpella, E.
Monroig, R,
Thompson, D,
Rechtine, D., Impact
of DOT on outcomes
in HIV clinical trials.
7th Conference on
Retroviruses and
Opportunistic
Infection, Chicago,
IL, February 2000,
Abstract  71.
ECONOMIC
OUTCOMES
Telemedicine
Cost per encounter
Patient Satisfaction
Texas
95% of telemedicine
encounters pre-
empted an onsite
visit, reducing costs;
69% of inmates pre-
fer telemedicine to
travel. 
D. Paar,
Telemedicine in
Practice; HEPP
News Vol 3 (5). May
2000.  RM Brecht,
CL Gray, C
Peterson, B
Youngblood, UTMB-
Texas DOC Tele-
medicine Project,
findings from the
first year of opera-
tion, Telemedicine
Journal Vol 2. no 1.
1996.
BEHAVIORAL
OUTCOMES
Pre-release Peer
Education
Adherence to 
medication
Medication 
acceptance
California
California peer 
educated patients
were more likely to
"report" condom use
(38% vs 20%, p =
0.05).
Grinstead O, Zack
B.  Collaborative
research to prevent
HIV among male
prison inmates and
their female part-
ners.  Health
Education and
Behavior, 1999; 26:
225-257.
CORRECTIONAL
OUTCOMES
Discharge planning
with careful linkage
to community health
centers
Recidivism
Viral load on return
to prison
North Carolina
Patients returning to
prison after a period
of release have
poorly controlled
HIV. 
Stevenson B, Wohl
D. et al. Release
from prison is asso-
ciated with
increased HIV RNA
at a time of reincar-
ceration. XIII
International AIDS
Conference 2000,
Durban, South
Africa.Abstract
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Table 1. Correctional Outcomes Studies 
Dear Colleagues,
The 24th NCCHC in St. Louis had so much for everyone in the field it is difficult to pinpoint
any one salient feature. Yet...a special moment is indelibly etched in my mind. At the open-
ing ceremony, a number of correctional physicians grilled Reverend Jessie Jackson with
pointed medico-social questions. The Reverend did not miss a beat, but some of his
answers did not convey the flavor of staff research. It seemed that he had not previously
heard some of the novel questions posed by a few well meaning, corrections-savvy NCCHC
attendees.
After the HEPP Seminar, SCP Meeting and full-length NCCHC proceedings, I had the
impression that the near 2,000 attendees had satisfied (and then some) their thirst for cor-
rectional health care knowledge. With so much on everyone’s plate, we were fast approach-
ing the point of correctional health care information overload. However, one cannot have too
much of a good thing. I just hope the next joint meeting duplicates or enhances the St. Louis
performance.
This issue of HEPP News features a report on the HEPP-run "Outcomes" symposium at the
NCCHC conference.  Information on research studies preformed in correctional settings is
provided in the main article, and an update on the CDC/HRSA research initiative is featured
in our spotlight.  We’ve also provide you with a few websites that may assist you with obtain-
ing and planning your own outcome studies.  In addition, our HEPPigram this month
addresses differential diagnosis of skin rashes, and our HIV 101 reminds you of effective
prophylactic interventions for Opportunistic Infections.
After reviewing this issue, readers should be able to diagnose different presentations of
rashes, identify which preventative treatment is appropriate for opportunistic infections in
HIV infected patients, and identify the benefits of HIV interventions outcomes research.
In the next issue of HEPP, Mary Sylla will review legal issues in corrections and we’ll pro-
vide an update on what has happened with clinical trials in corrections since our conference
one year ago.  As usual, we welcome any feedback or written contributions!
Sincerely,
Joseph Paris, M.D., Ph.D., C.C.H.P.
Guest Editor
Letter from the Editor
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4Highlighting the Need for
Research
In keeping with the theme of the HEPP sym-
posium, many other speakers at NCCHC
addressed research in correctional settings.
Steven Spencer, Jaye Anno, and Joseph
Paris presented on "Emerging Research
Topics/Issues in Correctional Health Care."
Anno noted that correctional healthcare
providers are 20 years behind other medical
groups in terms of knowledge of our
patients. Paris noted that there are unique
medical issues in corrections with which
community clinicians do not have to con-
tend. Spencer sees an overall change in the
trends of correctional research from measur-
ing prevalence of certain conditions to actu-
ally measuring outcomes of corrections-
based interventions.
Anno, Spencer, and Paris urged corrections
physicians to conduct research concerning:
inmate co-pay systems, obesity, dietary
management (heart-healthy diet versus nor-
mal diet), conditions of confinement (such as
the impact of having athletic facilities), the
health needs of women, the impact of men-
tal health problems on healthcare, dental
needs, women’s use of health services, par-
enting issues, and lastly, data management.
Anno closed by addressing the fact that
many correctional physicians claim that
obstacles to care include insufficient staff,
time, money, and commitment.  
She asked the probing question, are these
barriers or excuses?
Summary
There is much to do in the field of outcomes
measures in correctional settings. As Jaye
Anno noted, we as correctional healthcare
providers know very little about our patients
as a whole.  We have seen, however, many
promising HIV care interventions, and are
learning which ones work best.
Furthermore, judging by the number of par-
ticipants at our NCCHC meeting, outcomes
research is of increasing interest to our col-
leagues. For more information on grants for
outcomes research, see our resources on
page 8.
For a complete listing of the sessions or
more information, contact the NCCHC at
ncchc@ncchc.org.
Update from the
24th NCCHC... 
(continued from page 2)
References:
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Table 2. Other NCCHC Highlights Joseph E. Paris, M.D., Medical Director, Georgia Department of Corrections
Meeting of SCP
The annual meeting of the Society of Correctional Physicians  (SCP) was its most successful ever and it preceded and enhanced the
NCCHC Meeting. Many correctional physicians joined the SCP in St. Louis. SCP President Dr. Joseph Paris from the Georgia DOC
introduced Dr. Jennifer Clarke from the RI DOC, who presented an Overview of Women’s Wellness, Dr. Norman Johnson of Health
Professionals, who reviewed Geriatric Issues of Incarcerated Females, Dr. Rosemary Jackson, Ms. Jennie Lancaster, and Ms. Betty
Rider, of the North Carolina DOC, who addressed the Difficulties of Health Services and Custody Working Together, and Dr. Kathryn
Anastos, of the Albert Einstein College of Medicine, who discussed Gender and Ethnic Differences in HIV Patients. The meeting closed
with an open forum on Women’s Health Issues.
Among the many NCCHC Concurrent Sessions, the following sessions stand out:
G Staff from the Hampden County Correctional Center presented a successful public health model of health care for corrections 
consisting of a three-year evaluation and research of the measurable benefit and favorable outcomes of their model.    
G Another seminar addressed the rights of medical professionals facing the option of settling a civil lawsuit. Robert Vogt analyzed 
insurance policies, consent issues, impact of the settlement on regulatory and reporting agencies and confidentiality.
G Drs. Spaulding and Clarke, and staff from the RI  DOC had sessions on "Developing an Algorithm for Testing Jail Entrants for 
Sexually Transmitted Diseases" and related topics.
G "Domestic Violence Issues for Correctional Health Care Professionals" were explored by Dr. Diane Rechtine and others from the 
Florida Department of Corrections.
G William  Rold,  JD, CCHP, noted correctional attorney, described the latest developments in the laws effecting the provision of 
health care to incarcerated individuals.
G A dental presentation by Thomas Shields II, DDS, CCHP, and Gregory Becker, DM, of the Florida Department of Corrections, 
dealt with periodontal disease and associated bacteria and their link to numerous systemic diseases including infective endocarditis, 
cardiovascular disease, atherosclerosis, respiratory disease, and diabetes, as well as various bacteremias in correctional facilities.
G Richard Novack presented the latest concerning nelfinavir dosing. Although pharmacokinetics of nelfinvavir might predict that TID 
dosing would be superior to BID dosing, the improvement in adherence that occurs from switching to BID actually results in better 
treatment outcomes.
G The geriatric inmate was covered by Norman Johnson, MD, Health Professionals LTD, Karen Stocke, RN, Stephen Cullinan, MD, 
and Adrian Feinerman, MD.
G Dr. Joseph Paris presented the HIV + Inmate Post Release Program of the Georgia Department of Corrections, aimed to ensure 
continuity of HAART after release to society.
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PREFERRED PREVENTION
TMP-SMX 1 DS/day or 1
SS/day (A I)*
G INH 300 mg/day + pyri-
doxine 50mg/day > 270
doses, 9 mos. or up to 12
mos. with interruptions. (A
II)
G INH 900mg + pyridoxine
100mg 2x/wk with directly
observed therapy,  > 76
doses, 9 mos. or up to 12
mos. with interruptions (B I)
G Patient not receiving PI
or NNRTI:  Rifampin
600mg/day + pyrazinamide
20mg/kg/day with > 60
doses x 2 mos. or up to 3
mos. with interruptions (A I)
TMP-SMX 1 DS/day (A II)*
Clarithromycin 500mg or bid
(A I)  or azithromycin
1200mg po weekly (A1)
VZIG 5 vials (6.25mL) IM
within 96 hours of expo-
sure, preferably within 48
hours (A III)
ALTERNATIVES
G TMP-SMX 1 DS 3x/wk (B I)
G Dapsone 100mg qd or 50mg po bid (B I)
G Dapsone 50mg qd plus pyrimethamine 50mg/wk plus leukovorin 
25mg/wk (B I)
G Dapsone 200mg/wk plus pyrimethamine 75 mg/wk plus leukovorin 
25mg/wk (BI)
G Aerosolized pentamidine 300mg q mo
G Atovaquone 750mg po bid with meals (NEJM 1998;2\339:1889) (B I)
Patients receiving a PI or NNRTI need rifabutin in place of rifampin/pyrazi-
namide 20mg/kg and dose adjustment of the antiretroviral agent (B III).
G Amprenavir-standard; rifabutin-150 mg/d
G Efavirenz-standard; rifabutin-450mg/d
G Indinavir -- 1200mg q8h; rifabutin -- 150mg/d
G Nelfinavir -- 1000mg tid; rifabutin -- 150mg/d
G Ritonavir -- standard dose; rifabutin -- 150mg qod
Note: Rifabutin should not be combined with delavirdine and dose sched-
ules are not available for Fortovase.  Rifabutin should be combined with
pyrazinamide 20mg/kg/day with > 60 doses x 2 mos. or up to 3 mos. with
interruptions (B III)
Rifampin 600mg qd x 4mos. (B III)
Contact with INH resistant strain: Rifampin plus pyrazinamide x 2 mos.
(Above doses) (A I)
Alternative: Rifabutin/pyrazinamide (above doses x 2 mo.) (B III); Rifabutin
300mg po qd x 4 mo. (C III)
Contact with strain resistant to INH and rifamycin: use 2 agent with
anticipated activity-ethambutol/pyrazinamide or levofloxacin/pyrazinamide
Pregnancy: INH regimens
TMP-SMX 1 SS/day (B III)
G Dapsone 50 mg po qd plus pyrimethamine 50mg/wk plus 
leukovorin 25 mg po/wk (B I)
G Dapsone 200mg po/wk plus pyrimethamine 75 mg po/wk plus 
leukovorin 25 mg po/wk
G Atovaquone 1500mg qd – pyrimethamine 25mg qd + leukovorin 
10mg qd (C III).
Rifabutin 300 mg po qd (B I) or azithromycin 1200 mg/wk plus rifabutin
300mg qd (C I) (check rifabutin dose adjustment for use with PIs or
NNRTIs)
Prophylactic acyclovir was included in the 1995 USPHS/IDSA Guidelines,
but was deleted from the 1999 version due to lack of supporting clinical evi-
dence of efficacy.
Prevention of Opportunistic Infections. The following are recommended as standard of care.
Rating systems for strength of recommendation
A: Both strong evidence for efficacy and substantial clinical benefit support recommendation for use.  Should always be offered.
B: Moderate evidence for efficacy-or strong evidence for efficacy, but only limited clinical benefit-supports recommendation for use. 
Should generally be offered.
C: Evidence for efficacy is insufficient to support a recommendation for or against use, or evidence for efficacy may not outweigh 
adverse consequences (e.g. toxicity, drug interactions, or cost of the chemoprophylaxis or alternative approaches).  Optional.
Categories Reflecting Quality of Evidence Supporting the Recommendation 
I: Evidence from at least one properly randomized, controlled trial.
II: Evidence from at least one well-designed clinical trials without randomization, from cohort or case-controlled analytic studies 
(preferably from more than one center), or from multiple time series studies or dramatic results from uncontrolled experiments.
III: Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.
Adapted from Bartlett JG and Gallant JE.  2000-2001 Medical Management of HIV Infection.  Johns Hopkins University, Baltimore, MD. 2000.
*Bactrim is preferable because it prevents two illnesses: Pneumocystis carinii and Toxoplasma gondi.
RISK
CD4 count
<200/ mm3,
prior PCP or
HIV-associated
thrush or FUO x
2wks  (A II)*
Positive PPD
(>5 mm indura-
tion) with prior
treatment (A I),
recent TB con-
tact (A II) or his-
tory of inade-
quately treated
TB that healed
(A II)
CD4 count
<100/ mm3 plus
positive IgG
serology for T.
gondii
CD4 count <50
mm3
Significant
exposure to
chickenpox or
shingles who
are either
seronegative 
for VAV or have
no history of 
primary or 
secondary VZV
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6HEPPigram
Differential Diagnosis of Rashes in HIV-Infected Patients
DIFFUSE LOCALIZED
Lobulated nodules,
any place on skin.
Bacillary
angiomatosis
Seborrhea
Dermatophytes
Kaposis’s 
sarcoma
Prurigo nodularis
Scabies 
HIV-Associated
Pruritis
Drug reaction
Asteototic
eczema
Scaling, patches and plaques on
scalp, central face, ears, chest,
upper back, axillae, and groin.
Scaly, annular plaques with active
borders and central clearing lesions
involving skin or nails.
Firm, dark colored, slightly
raised macules, papules,
plaques and nodules.
Hyperpigmented, hyperkeratotic,
often excoriated, associated 
w/ other signs of chronic
pruritis/excoration.
Excoriated, crusted pinhead-sized
papules; burrows; intense general-
ized pruritis that is worse at night.
(May be localized but often dissemi-
nated in HIV-infected patients).
W/out cutaneous lesions
except excoration.
Morbilliform exanthum – pruritis;
less common-urticaria, erythema
multiforme, TEN, pityriasis 
rosea-like eruption.
Patches and plaques with 
varying degrees of erythemia,
scaling, crusting, and l
ichenification.  Diffuse dry skin 
is always present.
For treatment of rashes, see the reference for this flowchart, Table 7-10: Dermatologic Complications in Patients with AIDS in Bartlett
JG and Gallant JE.  2000-2001 Medical Management of HIV Infection.  Johns Hopkins University, Baltimore, MD. 2000.
Scaling, patches and
plaques on elbows,
knees, scalp, lum-
bosacral area, – nail
changes and arthritis.
Psoriasis
Syphilis
Photosensitivity
Candidiasis 
Molluscum 
contagiosum
"Fever blisters"
Herpes simplex I
Herpes simplex
Herpes zoster
Folliculitis (S.
aureas,
Pityrosporum
ovale, Demodex
folliculorum,
eosinophilic
inflammation)
Icthyosis vulgaris
Erythmatous macules and papules
involving trunk, extremities, palms
and soles (Secondary syphilis);
chancre (primary syphilis).
Sun-exposed areas- hyperpigmen-
tation, eczematization, may blister.
Large, beefy red lesions
w/satellite papules on
groin area, under breasts,
and axillae.
White or flesh-colored papules
w/central umbilication, present on
face (beard area), neck, genital
region (can be diffuse).
perioral
Perianal and/or genital.
Unilateral dermatomal 
distribution associated with
neuralgia and crusting in
later stages.
Pruritic follicular papules and 
pustules, face, trunk, extremities.
(If localized on web of hands and
feet, see scabies).
Polygonal shaped
scales on extensor 
surfaces of arms 
and legs.
Erythematous
Papules
Blisters
Scales
Pruritis
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A year ago, departments of corrections in seven states received a mil-
lion dollars each in CDC/HRSA grant money. California, Florida, Illinois,
Georgia, Massachusetts, New Jersey, and New York are using the
funding to create stronger ties and linkages between HIV-infected
inmates and community health care providers with an eye toward
improving continuity of medical care after release.  One year later, CDC
officials are beginning to evaluate the progress of these grantees and
their programs with the hope of eventually identifying a model for com-
munity linkages for other corrections jurisdictions. 
The goal of the CDC/HRSA initiative was to target African Americans
and other racial minorities, increase access to HIV/AIDS primary health
care and prevention, improve transition between correctional facilities
and the community for HIV positive offenders and develop support in
the community for HIV health and social services. "The emphasis is to
focus on folks who are HIV positive and those who have been dispro-
portionately impacted as well as those with any other behavioral risks,
TB, hepatitis-and we can’t ignore substance abuse. They all roll into
one," said John Miles, of the Centers for Disease.
Dr. Kimberly Arriola, a member of the Evaluation & Program Support
Center (EPSC) team at Emory University in Atlanta, summarized the
current status of the projects at the HIV/AIDS Behind Bars 2000 Pre-
Conference Symposium, National Commission on Correctional Health
Care Conference, St. Louis, MO. Other members of the EPSC team
include Ronald Braithwaite, Ph.D. (project principal investigator), and
Alyssa Robillard, Ph.D. Additional members include Theodore
Hammett, Ph.D. (Co-Principal Investigator) and Sofia Kennedy, MPH of
Abt Associates (Cambridge, MA).
Dr. Arriola emphasized that correctional settings are ideal for preven-
tion and treatment interventions, and that HIV treatment, management,
and prevention interventions to date appear to have been inadequate.
Therefore, the goal was not to fund improved HIV care, but rather to
model how linkages to the community can address the problem of HIV
management in corrections. 
Evaluation Objectives
The objectives of the evaluation are to document the process of pro-
gram implementation, and to describe the challenges & strategies, and
determine whether the interventions are building on existing programs
or forging new collaborations. The grantees were to demonstrate the
range & volume of services provided and examine client-level out-
comes for selected intervention components. Furthermore, they were
to show linkage with key services in the community; utilization of care;
and the impact of their interventions on HIV risk reduction.
"We are looking at which [program style] is better. Giving someone a
referral card is nice, but a phone call, appointment and a face-to-face
hand-off is even better. Hopefully in the long run, if we do all of this well,
we will see if it has an impact in recidivism and reducing [disease]
transmission," said Miles.
The program features a "constellation" of interventions (HIV treatment,
Case Management, Discharge Planning, Prevention Case
Management) along with HIV prevention (Educational sessions, peer-
based programs), disease screening, and staff training in a range of
settings in prisons, jails, and juvenile facilities.
Evaluation Activities
During year one, the evaluators learned about the grantees via site vis-
its and meetings  (obtaining buy-in was important!). According to
grantees, one of the major impediments to the development of pro-
grams was the lack of existing research and programmatic infrastruc-
ture, such as experience with IRB approval of projects to be carried out
in correctional settings, (see main article).  
Some of the information that will soon be available includes information
gathered during intake (jail or prison) such as discharge planning
needs, health status, health  care utilization, alcohol and drug use and
treatment, and client demographics. In addition, information will be
gathered from the medical record such as the client’s HIV status,
whether the client was tested during that incarceration, and mental ill-
ness diagnoses. At release, the staff will evaluate the final discharge
plan and perform a medical record abstraction. Even more importantly,
during Post-Release Services, staff will report at 30-day intervals on
medical & mental health care, treatment, housing, benefits, and
employment (see Table 1).
In addition, the researchers will conduct offender interviews as they go
through the discharge process. "We will be doing a baseline and a fol-
low-up interview with participants either three months post the last con-
tact with the intervention in the community or 6 months past release,
whichever come first," said Ted Hammett of Abt Associates. 
According to Hammett, the follow-up interview with clients will be a self
report where investigators will look at whether linkages were made and
if the clients were able to access them.
Expected Challenges
CDC officials are well aware that corrections and public partnerships
can be challenging to develop depending on the jurisdiction. 
"We’re very fortunate in the states that competed [for the grants]. They
are all states with major problems with the burden of disease [and the
community was open to partnerships]," Miles said. "In general there’s a
real recognition that keeping the inmate population healthy is part of
improving the safety and well being of the institution. It also bodes well
with the community trying to build the collaboration; that needs to be
there."
In January, CDC officials and grantees will meet to discuss any hurdles
experienced along the way to creating the community linkages for HIV-
positive offenders.  
Conclusion
Evaluation of  the outcome of this CDC/HRSA Initiative is likely to offer
insight on what factors influence engagement & maintenance in post-
release medical care. Although the researchers have encountered sev-
eral obstacles and experienced delays in data gathering, the initiative
has potential to make a major impact on public health policy and estab-
lish models for implementation elsewhere.
At the HEPP symposium, audience participants were informed that the CDC
study forms would be available to other individuals interested in collecting
data. Contact Dr. Arriola at Emory University or Dr. John Miles at the CDC
for additional information. Although no additional states or sites will receive
funding through this initiative, HEPP readers may find it useful to adapt the
CDC/HRSA forms to their own projects. Information about other potential
sources of funding for HIV intervention projects is available from the web-
sites sited in the resource section of this issue.
Spotlight:
G Started on HAART
G Are receiving Case management or 
discharge planning M/DP
G Released with referrals/appointments
G Released with HIV medications
G Single sessions or series of sessions
G Unduplicated number of participants
G Demographics (series participants)
G Percentage completing every session in series
G Spanish-language sessions
G Sessions conducted by peer educators
G Length of sessions
G Number of peers recruited
G Number of recruits who completed training
G Demographic characteristics of peer 
educators
G Disease Screening (by disease entity)
G Tests• positive tests
G Results not received
G Partner notification/contact tracing
G Treated/started on treatment
G Staff Training
G Single session/series of sessions
G Number eligible/attending
Treatment/Case
Management
HIV Prevention
Peer Educator
Training
Disease
Screening &
Staff Training
Table 1. Aggregate Data 
Federal Funding For HIV in Corrections: One Year Later  by HEPP Staff
Management of HIV/ AIDS in the
Correctional Setting: A Live 
Satellite Videoconference Series, 
Antiretroviral Update 2000
Available for online viewing at 
your convenience after October 16
at the HEPP News Website: 
http://www.hivcorrecttions.org 
2.5 CME credits available 
from Albany Medical College
Corrections to Community: 
Continuity of Care
A one-day discharge planning training
presented by SEATEC.
November 9, 2000, Gainsville, GA
December 7, 2000, Forsyth, GA
January 10, 2001, Tifton GA
All trainings are free, provide lunch, 
and run from 9am to 4pm.
Contact: Marjorie Dunne at
seatec_training@hotmail.com
Call: 404.712.9687 
Visit: http://www.seatec.emory.edu 
American Public Health 
Association Annual Conference
November 13-16, 2000, Boston, MA
A number of correctional healthcare
topics will be featured.
To register, Call: 514.847.2293
Email: APHA@laser-registration.com.
Visit: www.apha.org
Request for Proposals (RFP): 
Equal Access Initiative- Computer
Grants Program 2000/2001.
Due Date: December 1, 2000
100 minority community-based
HIV/AIDS organizations will lreceive
access to the Internet through a unique
in-kind computer grants program.
Contact: National Minority AIDS Council
(NMAC) at 202.483.6622 
or info@nmac.org
Visit: www.nmac.org/pubs/
RFP2000-2001.htm
National STD Prevention Conference
December 4-7, 2000
Milwaukee, WI  
Contact: Glenda Vaughn, Centers for
Disease Control and Prevention 
Call: 404.639.1806 
E-mail: ghv1@cdc.gov 
Medical Management of AIDS: A
Comprehensive Review of HIV
Management - Winter Symposium
December 7-9, 2000
San Francisco, CA
Contact: Cliff Brock
Department of Medicine UCSF
Call: 415.476.5208
Fax: 415.476.3542
Email: cme@medicine.ucsf.edu
Web: http://medicine.ucsf.edu/
programs/cme
2001 ACA Winter Conference 
January 22-24, 2001
Nashville, Tennessee 
Call 1-800-222-5646, ext. 1922 
Fax: 1-301-918-1900
Visit: www.corrections.com/aca
Save the 
Dates
News Flashes
New Complication of HIV:
Osteonecrosis of the Hip
Investigators at the National Institutes of Health
(NIH) have demonstrated that a disabling bone
disorder, osteonecrosis of the hip, is surprisingly
common among patients with HIV infection.
Concern that the disorder might be a new and
unrecognized complication of HIV infection
prompted the investigation, a collaboration
between the NIH Clinical Center and the
National Institute of Allergy and Infectious
Disease (NIAID).  Magnetic resonance imaging
was used to evaluate 339 study volunteers, all
patients with HIV.  While none of the study par-
ticipants had the hip pain typically associated
with osteonecrosis, 15 (4.4%) were found to
have the disorder.  One concern is that the
lesions will lead to clinical symptoms that ulti-
mately require total hip replacements.  The rea-
son for this unexpected complication of
osteonecrosis (bone death) is unclear. A longitu-
dinal study is under way to determine how
many patients will develop these lesions and
how many will ultimately need hip replacement.
(NIH News Release, Clinical Center
Communications).
Kentucky Inmates to receive medical
care for hepatitis C
A few months after a federal magistrate con-
demned the Kentucky Corrections Department
for denying medical treatment to a prisoner with
life-threatening hepatitis C, the agency adopted
a new plan that could mean up to 1,000
inmates will get the care, at a cost of $25,000
per patient.  The department currently is testing
800 to 1,000 inmates who have the viral infec-
tion, a leading cause of liver disease, to see
who will qualify for the expensive drug therapy.
The Correction Department’s new plan provides
treatment to inmates with  liver disease who
meet all of eight qualifications, including the
willingness to undergo random drug tests.
Prisoners are excluded for any of  17 reasons,
including "high-risk behavior" after their diagno-
sis, such as  "sexual behavior, body piercing
and tattoos." Patients also are excluded if they
are scheduled to meet the parole board  within
18 months so that treatment does not have to
be terminated if an inmate is released (Wolfson,
A.  The Courier-Journal, September 21, 2000). 
"Liver Failure Common in HIV-
Infected Patients"
A report in the September issue of the Journal
of Acquired Immune Deficiency Syndrome
shows  that HIV-infected individuals often die
from liver failure.  Italian researchers studied
1,900 HIV-infected patients for eight years, dur-
ing which time there were 467 deaths.  Among
the 308 in-hospital deaths, AIDS was a key fac-
tor in 89% of the deaths, while liver failure was
the primary cause of death for 5% of the
patients and a concurrent cause of death in an
additional 6%. Dr. Massimo Puoti-who also
found that 80% of the patients who died in the
hospital tested positive for antibodies to hepati-
tis C-said that key strategies to prevent liver
failure among HIV-infected individuals include
working to prevent hepatitis B, treating existing
hepatitis B infections, and reducing alcohol use.
(Puoti et al. JAIDS, Sept 18 2000;24:211-217.)
A corrections edition of Bartlett and
Gallant’s 2000-2001 Medical
Management of HIV Infection is now
available. The only difference between the
corrections edition and the regular edition is the
first chapter.  The HIV Management Guidelines
are outlined in this book and updated every
week on the web at http://www.hopkins-
aids.edu. 
HRSA’s HIV/AIDS Bureau has recently
published A Guide to the Clinical
Care of Women with HIV. This 2000
Preliminary Edition is available at no cost and
will be updated at http://www.hrsa.gov/hab.
Expert Perspectives: 
Strategies for the Management 
of HIV/HCV Co-infection
Dr. Douglas Dieterich of Cabrini Medical Center
and Drs. John Bartlett and Mark Sulkowski of
Johns Hopkins University School of Medicine
recently co-chaired a meeting of researchers
and experts on HIV and hepatitis to assemble
guidelines for the treatment of HIV and hepatitis
C co-infected patients. The guidelines appear
online in a continuing medical education 
monograph at http://www.projectsin
knowledge.com/hiv-hcv/index.html 
Grant and Funding Websites
NIH Grants and Funding Opportunities
http://grants.nih.gov/grants/index.cfm
CDC’s Procurement and Grants Office
http://www.cdc.gov/od/pgo/funding/
grantmain.htm
Guide to Winning Grants
http://www.grantstech.com/
Grantspring
http://www.grantspring.com/research.htm
HIV Treatment Websites
AIDSline
http://www.igm.gov
National Institute on AIDS
http://www.niaid.nih.gov
Virology on the Web
http://www.virology.net
Health Resources and Services
Administrations HIV/AIDS Bureau
http://www.hrsa.gov/hab
National Commission on 
Correctional Health Care
http://www.ncchc.org
Resources & Opportunities
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Self-Assessment Test for Continuing Medical Education Credit
Brown University School of Medicine designates this educational activity for 1 hour in category 1 credit toward the AMA Physicians
Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of
the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through 
Nov. 30, 2000. The estimated time for completion of this activity is one hour and there is no fee for participation.
1. A patient presenting scaling, patches, and plaques with active
borders and central clearing lesions involving skin or nails may
have:
a) Psoriasis
b) Candidiasis
c) Icthyosis vulgaris
d) Scabies
e) Dermatophytes
2. A patient presenting with pruritic papules and pustules on web
of hands and feet may have:
a) Drug reaction
b) Psoriasis
c) Folliculitis
d) Scabies
e) Dermatophytes
3. The preferred prevention for Toxoplasma gondii is:
a) Dapsone 100mg qd
b) Dapsone 50mg po qd plus pyrimethamine 50mg/wk plus 
leukovorin 25mg po/wk
c) TMP-SMX 1 DS/day
d) Clarithromycin 500mg 
4. Indicate which of the following statements is true:
a) The lifespan of an HIV-infected person on HAART with 
CD4<100 is close to that of someone who is 
HIV-seronegative.
b) HIV drug resistance is less common in inmate 
populations than in the general population.
c) HAART is a less expensive intervention per year of life 
saved than mammography or coronary artery bypass.
5. Strategies for preventing liver failure in HIV infected patients
include:
a) Strategic treatment interruptions
b) Using enteric coated ddI (Videx) instead of the 
buffered ddI.
c) preventing Hepatitis B by vaccinating
d) a and b
e) All of the above
6. An HIV infected patient currently on protease inhibitors, was
recently exposed to an INH resistant strain of TB, and is now
PPD-positive.  The appropriate treatment for latent TB infection in
this case could be:
a) Rifampin 600mg/day + pyrazinamide 20mg/kg/day 
with  > 60 doses x 2 mos or up to 3 mos with interruptions. 
b) INH 300mg/day + pyridoxine 50mg/day  > 270 doses, 
9 mos. or up to 12 mos with interruptions
c) Rifampin + pyrazinamide 20mg/kg x 2 mos
d) Rifabutin.pyrazinamide 20mg/kg/day 
with = 60 dose x 2 mos. or up to 3 mos with interruptions; 
e) Rifabutin 300mg po qd x 4 mo.
f) a and c
g) d and e
h) All of the above
BROWN UNIVERSITY SCHOOL OF MEDICINE  OFFICE OF CONTINUING MEDICAL EDUCATION  BOX G-A2  PROVIDENCE, RI 02912
The Brown University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor 
continuing medical education activities for physicians.  
The use of the Brown University School of Medicine name implies review of the educational format and material only.  The opinions, 
recommendations and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or 
speak for the Brown University School of Medicine.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660
Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP News Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1   
HEPPigram 5  4  3  2  1   5  4  3  2  1   
HIV 101 5  4  3  2  1   5  4  3  2  1   
Spotlight 5  4  3  2  1   5  4  3  2  1
Save the
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP News helps you in your work?
Why or why not?
3. What future topics should HEPP News address?
4. How can HEPP News be made more useful to you?
5. Do you have specific comments on this issue?
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